November 7, 2016
“We appreciated our interaction with the DMC and are pleased that they have recommended the ACCUTE study continue as designed,” said Dr. Wayne Dankner, Chief Medical Officer of Atox Bio.  “A treatment is needed for this devastating condition and we are hopeful that AB103 will be the first product specifically approved for NSTI. We are...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge